Sun Pharma gets CCI nod to sell two CNS divisions to Strides Shasun for Rs 165 crore

Published On 2016-01-23 06:21 GMT   |   Update On 2016-01-23 06:21 GMT
Advertisement
NEW DELHI: Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.

The company has received an order under the Competition Act, 2002, from the Competition Commission of India (CCI) approving the proposed transaction, Sun Pharmaceutical Industries said in a regulatory filing.
Advertisement

"With this approval, all necessary regulatory approvals have been obtained," it added.

Last year in September, Sun Pharma and Strides Shasun (then Strides Arcolab) had inked a pact related to Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India.

The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore.

Sun Pharma acquired Ranbaxy Laboratories in a USD 4 billion deal in 2014.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News